|
Biotie Therapies - Company Profile Snapshot
| Company Profile: |
Biotie Therapies |
| Ticker: |
BTH1V |
| Exchanges: |
DUS FRA HEL OTH |
| 2008 Sales: |
5,127,000 |
| Major Industry: |
Miscellaneous |
| Sub Industry: |
Medical Services |
| Country: |
FINLAND |
| Employees: |
80 |
Business Description
Biotie Therapies. The Group's principal activity is the research and development of drugs for dependence disorders, inflammatory diseases, glycomics applications and thrombosis. This is the Group's only segment. The Group's products focus on widespread diseases such as alcohol dependency, rheumatoid arthritis, inflammatory bowel disease, psoriasis, thrombosis and cancer. The Group's 'nalmefene' is the first tablet form drug demonstrating efficacy in reducing heavy drinking in multicenter. Other products include VAP-1 monoclonal which I s an antibody for inflammatory diseases, VAP-1 SSAO is enzyme inhibitor for inflammatory diseases and Integrin 2 B1 is inhibitor for thrombosis. The Group operates in Finland and Germany. The Group acquired CNS and inflammation specialist elbion GmbH in 2008.
|
Not the Report you are looking for?
Click here for more browsing options.
|
The following information is available to subscribers or can be accessed by purchasing the Company Profile Report:
|
- Address (mailing), Phone Number, Web Address
- Earnings/Dividends
- Employees
- Exchanges Listed
- Financial Ratio Analysis |
- Recent Stock Performance
- Sales (recent year)
- Senior Officers
- Shareholder Information
- Stock Analysis Summary |
Layout and Content of a Typical Report
|
|
|
|
|
